// App-Quantinova.ai

: Phase I Clinical Trial to Evaluate the Safety of Baricitinib to Prevent Respiratory Insufficiency Progression in Oncohematological Patients Affected with COVID-19 - BARCOVID19 Study

Researchers

Presenter

  • Gabriela Sanz-Linares

Principal Investigators

  • Alberto Mussetti

  • Adaia Albasanz-Puig

  • Iñaki Salvador-Corre

  • Anna Sureda

  • Carlota Gudiol

  • Ramon Salazar

  • Mar Marin

  • Margarita García Martín

  • Valentin Navarro

  • Irma De la Haba

  • Eva Coma

  • Xavier Dura

  • Sandra Fontanals

  • Gala Serrano

  • Claudia Cruz

  • Rafael Mañez

  • Gabriel Moreno-González

Medical Centers

  • Department of Hematology, Hospital Duran i Reynals, Instituto Catalán de Oncología, L'Hospitalet De Llobregat, Barcelona, Spain

  • Intensive Care Department, Hospital Universitari de Bellvitge, barcelona, Spain

  • Clinical Trials Unit, Institut Català d'Oncologia, Barcelona, Spain

  • Palliative Care Department, Institut Català d'Oncologia, barce, Spain

  • Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet De Llobregat, Barcelona, Spain

  • Oncology Emergency Unit, Institut Català d'Oncologia, Barcelona, Spain

  • Pharmacology Department, Institut Català d'Oncologia, Barcelona, Spain

  • HEMATOLOGY, INSTITUT CATALA D'ONCOLOGIA, BARCELONA, Spain

  • Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL); Biomedical Research Institute, Universitat de Barcelona, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Tocilizumab

  • Baricitinib

Outcome

  • N/A

Study Design

  • Safety

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved